PHILADELPHIA, PA--(Marketwire - November 12, 2008) - ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announces today that the United States Food and Drug Administration ("FDA") has approved the Company's Investigational New Drug Application ("IND") for the treatment of asthma. This approval enables the Company to proceed with Phase I clinical trials in humans for its asthma drug candidate, Excellair™. The IND review included ZaBeCor's clinical development plan, Phase I clinical trial protocols, manufacturing plans and extensive pre-clinical studies.
